Aug 2009 to 2000 Staff Business AnalystIntuit Plano, TX Aug 2003 to Jul 2009 Sr. Business Systems Analyst
Education:
Southern Methodist University Dallas, TX 2003 MBA in Information Technology / Operations Management
Skills:
Expert-level understanding of business process analysis and management techniques, along with requirements development, Experience using agile and waterfall project delivery methodologies, Change leader with significant experience with process and application rollouts, Excellent written and Oral Communication, Application Testing experience building testing plans and scripts, Experience working with and managing Vendor Relationships, Post Production Support, Extensive data analysis skills, including building relational database applications using Intuits QuickBase application
Michael Gregory Bell - Indianapolis IN Michael Edward Le Tourneau - Indianapolis IN Michael John Martinelli - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D21706
US Classification:
514307, 5142315, 544128, 546146
Abstract:
The present invention provides compounds of formula (I): wherein W represents hydrogen, C -C alkyl, âCH CO H, or CO H; and X represents hydrogen, C -C alkyl, âCH CO H, or CO H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
5-Deaza-10-Oxo- And 5-Deaza-10-Thio-5,6,7,8-Tetrahydrofolic Acids
Homer L. Pearce - Indianapolis IN Mark A. Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07C 2900
US Classification:
560 39
Abstract:
5-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treating susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.
Michael Gregory Bell - Indianapolis IN Thomas Alan Crowell - Indianapolis IN Donald Paul Matthews - Indianapolis IN John Hampton McDonald - Carmel IN David Andrew Neel - Zionsville IN Anthony John Shuker - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31415 A61K 3140 C07D20908 C07D23526
US Classification:
514359
Abstract:
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective. beta. 3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formula II: ##STR1## The variables in Formula II are defined herein.
Benzo[B]Indeno[2, 1-D]Thiophene Compounds, Intermediates, Compositions, And Methods
Michael Gregory Bell - Indianapolis IN Brian Stephen Muehl - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C07D33350
US Classification:
549 42
Abstract:
The invention provides benzo[b]indenothiophene compounds, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
Michael Gregory Bell - Indianapolis IN Thomas Alan Crowell - Indianapolis IN Donald Paul Matthews - Indianapolis IN John Hampton McDonald - Carmel IN David Andrew Neel - Zionsville IN Anthony John Shuker - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31495 C07D40312
US Classification:
514248
Abstract:
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective. beta. 3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##.
Michael Gregory Bell - Indianapolis IN Brian Stephen Muehl - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31445 C07D40912
US Classification:
514324
Abstract:
The invention provides benzo�b!indenothiophene compounds of formula I ##STR1## wherein, R. sup. 1, R. sup. 2, R. sup. 3, R. sup. 4, R. sup. 5, and R. sup. 6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
Michael Gregory Bell - Indianapolis IN Thomas Alan Crowell - Indianapolis IN Cynthia Darshini Jesudason - Indianapolis IN Donald Paul Matthews - Indianapolis IN John Hampton McDonald - Carmel IN David Andrew Neel - Zionsville IN Christopher John Rito - Mooresville IN Anthony John Shuker - Indianapolis IN Mark Alan Winter - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3141 A61K 31415 C07D27112 C07D23504
US Classification:
514362
Abstract:
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective. beta. 3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: ##STR1##.
Srinivasan Chandrasekhar - Indianapolis IN Anne H. Dantzig - Crawfordsville IN Robert L. Shepard - Noblesville IN James J. Starling - Carmel IN Mark A. Winter - Indianapolis IN
The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.
Isbn (Books And Publications)
A Short Course in Creating What You Always Wanted to but Couldn't Before Because Nobody Ever Told You How Because They Didn't Know Either
Flower Mound, TXMark Winters is a seasoned professional with over 20 years of entrepreneurial leadership experience delivering a high level of success. His experience in... Mark Winters is a seasoned professional with over 20 years of entrepreneurial leadership experience delivering a high level of success. His experience in companies ranges from multi-billion dollar global enterprises like Procter & Gamble and British Petroleum, to raw startups drawn up on a napkin...
None of the men were tenants at the apartment in the Southside Works City Club Apartment building, said Mark Winter, a spokesman for the building, adding that the men had been visiting a tenant who was in good standing.
Date: Sep 22, 2019
Category: Headlines
Source: Google
Edvard Munch's The Scream Sells for a Record $120 Million at Auction
Mark Winter, director of Munch Experts, told the Guardian, It is the crown jewel of the four but you really need a national budget to buy it. And not the budget of a small country, either.Tobias Meyer, the Sothebys auctioneer, told Reutersthe bidder got a good deal.Its worth every penny that